Atlas Trials

Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia

Clinical trial NCT01513109 · UNKNOWN

Trial details

NCT number
NCT01513109
Sponsor
Jules Bordet Institute
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Acute Myelogenous LeukemiaMyeloid Leukemia in RemissionEffects of Immunotherapy
Start date
2011-12-01
Primary completion
2013-12-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.